JP2021523109A5 - - Google Patents

Info

Publication number
JP2021523109A5
JP2021523109A5 JP2020561057A JP2020561057A JP2021523109A5 JP 2021523109 A5 JP2021523109 A5 JP 2021523109A5 JP 2020561057 A JP2020561057 A JP 2020561057A JP 2020561057 A JP2020561057 A JP 2020561057A JP 2021523109 A5 JP2021523109 A5 JP 2021523109A5
Authority
JP
Japan
Prior art keywords
phenyl
alkyl
substituted
hydrogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523109A (ja
JP7089062B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030028 external-priority patent/WO2019213153A1/en
Publication of JP2021523109A publication Critical patent/JP2021523109A/ja
Publication of JP2021523109A5 publication Critical patent/JP2021523109A5/ja
Application granted granted Critical
Publication of JP7089062B2 publication Critical patent/JP7089062B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561057A 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホリジン Expired - Fee Related JP7089062B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862664850P 2018-04-30 2018-04-30
US201862664860P 2018-04-30 2018-04-30
US201862664891P 2018-04-30 2018-04-30
US201862664863P 2018-04-30 2018-04-30
US62/664,860 2018-04-30
US62/664,891 2018-04-30
US62/664,850 2018-04-30
US62/664,863 2018-04-30
PCT/US2019/030028 WO2019213153A1 (en) 2018-04-30 2019-04-30 Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Publications (3)

Publication Number Publication Date
JP2021523109A JP2021523109A (ja) 2021-09-02
JP2021523109A5 true JP2021523109A5 (cg-RX-API-DMAC7.html) 2022-04-20
JP7089062B2 JP7089062B2 (ja) 2022-06-21

Family

ID=66530472

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020561053A Active JP7204780B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるアシルホスホノアミダートおよびアシルベンジルアミン
JP2020560258A Active JP7080346B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホノアミダート
JP2020561057A Expired - Fee Related JP7089062B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホリジン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020561053A Active JP7204780B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるアシルホスホノアミダートおよびアシルベンジルアミン
JP2020560258A Active JP7080346B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホノアミダート

Country Status (6)

Country Link
US (5) US10738042B2 (cg-RX-API-DMAC7.html)
EP (3) EP3787626B1 (cg-RX-API-DMAC7.html)
JP (3) JP7204780B2 (cg-RX-API-DMAC7.html)
CN (4) CN110662752B (cg-RX-API-DMAC7.html)
CA (1) CA3056878C (cg-RX-API-DMAC7.html)
WO (3) WO2019213151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700075637A1 (it) 2017-07-05 2019-01-05 Vera Salus Ricerca S R L Composto per la cura dei tumori maligni
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
TWI731540B (zh) * 2019-01-04 2021-06-21 大陸商蘇州亞盛藥業有限公司 製備磺胺類藥物的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
CN114685856B (zh) * 2022-04-21 2024-02-20 兰州瑞朴科技有限公司 二乙基次膦酸铝的制备方法
CN118717761A (zh) * 2024-05-27 2024-10-01 复旦大学 瑞美吉泮在制备治疗/预防阿尔茨海默病药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266552A (en) 1991-11-12 1993-11-30 Imperial Chemical Industries Plc Arylphosphonoamidate herbicides
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
SK12442001A3 (sk) 1999-03-05 2002-06-04 Metabasis Therapeutics, Inc. Cyklické fosforamidáty, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
WO2004058267A1 (en) 2002-12-23 2004-07-15 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
CN101171241A (zh) * 2005-03-11 2008-04-30 密执安州立大学董事会 抗细胞凋亡的bcl-2家族成员的色烯-4-酮抑制剂及其应用
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009009041A2 (en) * 2007-07-06 2009-01-15 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CA2822039C (en) 2010-12-16 2019-05-28 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013052943A2 (en) * 2011-10-06 2013-04-11 The Regents Of The University Of Michgian Small molecule inhibitors of mcl-1 and uses thereof
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2945940B1 (en) 2013-01-16 2020-07-15 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
BR112015026702A2 (pt) 2013-04-21 2018-02-06 Yeda Res And Developmente Co Ltd métodos de extermínio de células senescentes
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) * 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
WO2015113944A1 (en) 2014-01-28 2015-08-06 Universiteit Gent Pyrabactin analogues to modulate plant development
EP3125943B1 (en) 2014-04-04 2026-04-22 Merck Sharp & Dohme LLC Phosphate based linkers for intracellular delivery of drug conjugates
CN106456699B (zh) 2014-05-05 2021-07-02 生物风险投资有限责任公司 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
CZ2014915A3 (cs) 2014-12-16 2016-02-24 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Substituovaný derivát kyslíkatých kyselin fosforu, jeho použití a farmaceutický přípravek ho obsahující
JP2018508569A (ja) 2015-02-06 2018-03-29 ユニティ バイオテクノロジー インコーポレイテッド 老化関連状態の治療における化合物および使用
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN107846899A (zh) 2015-07-15 2018-03-27 拜耳农作物科学股份公司 取代的氧代四氢喹啉基次膦酰胺和‑膦酰胺或其盐及其提高植物中的胁迫耐受性的用途
CN105646587B (zh) * 2016-03-02 2018-03-23 云南中医学院 1,3,2‑氧氮磷杂环戊烷类化合物、制备方法及应用
WO2019001171A1 (zh) 2017-06-27 2019-01-03 维眸生物科技上海有限公司 一种含磷化合物及其制备和应用
WO2019028391A1 (en) 2017-08-03 2019-02-07 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas DIALKYL PHOSPHONATE DIRECT METAL-FREE ARYLATION FOR THE SYNTHESIS OF MIXED ALKYL ARYLATED PHOSPHONATES
WO2019033122A1 (en) 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
CN111372598A (zh) 2017-08-11 2020-07-03 联合生物科技公司 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况

Similar Documents

Publication Publication Date Title
JP2021522270A5 (cg-RX-API-DMAC7.html)
JP2021523108A5 (cg-RX-API-DMAC7.html)
JP2022533398A5 (cg-RX-API-DMAC7.html)
JP2021535104A5 (cg-RX-API-DMAC7.html)
JP2023545396A5 (cg-RX-API-DMAC7.html)
JP2007504160A5 (cg-RX-API-DMAC7.html)
CA2796967A1 (en) Heterocyclic derivatives as alk inhibitors
JP2021502387A5 (cg-RX-API-DMAC7.html)
JP2005536475A5 (cg-RX-API-DMAC7.html)
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
JP2014526500A5 (cg-RX-API-DMAC7.html)
MX2013015370A (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cancer.
EP1986643A1 (en) Treatment of duchenne muscular dystrophy
JP2007519649A5 (cg-RX-API-DMAC7.html)
KR20050084271A (ko) 아미노인다졸 유도체 및 키나제 억제제로서의 이의 용도
RU2006126974A (ru) Амидное производное и лекарственное средство
JP2018502906A5 (cg-RX-API-DMAC7.html)
JP2010538094A5 (cg-RX-API-DMAC7.html)
JP7089062B2 (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホリジン
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2018522861A5 (cg-RX-API-DMAC7.html)
JP2022535734A5 (cg-RX-API-DMAC7.html)
RU2004107261A (ru) Арилсульфонильные производные, обладающие сродством к рецептору 5-нт6
CA2526989A1 (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
JP2014511865A5 (cg-RX-API-DMAC7.html)